Jacques Raynaud logo Fondation ARC logo

Jacques Raynaud

Member of Board and Past President, Fondation ARC for cancer research (France), Advisor to Operational Team, WIN Consortium


Jacques Raynaud has been Honorary Chairman of the ARC Foundation since October 2014 Scientific Advisor to the President and Knight of the French Legion of Honor.

Between 2002 and 2014, Jacques Raynaud was a member of the Board of Directors of the ARC Foundation of which he was Chairman between 2005 and 2014.

Previously, Jacques Raynaud spent most of his career in the pharmaceutical industry. After four years of research on behalf of Nestlé (Switzerland) and Esso Research (USA), he joined Roussel Uclaf in 1969 to become a member of the Directorate of Hoechst Marion Roussel France in 1998. Following the merger with Aventis he was appointed to head the Romainville Research Centre and joined the International Committee in Research and Development of Aventis.

The ARC Foundation is the first 100% French foundation dedicated to cancer research.
In 2014, the ARC Foundation spent nearly 28 million euros for its social missions. Its resources come exclusively from the generosity of its donors and testators.

Jacques Raynaud is WIN’s Advisor to the Operational Team.

Jacques Raynaud logo

Jacques Raynaud

Member of Board and Past President, Fondation ARC for cancer research (France), Advisor to Operational Team, WIN Consortium


Fondation ARC logo

Jacques Raynaud has been Honorary Chairman of the ARC Foundation since October 2014 Scientific Advisor to the President and Knight of the French Legion of Honor.

Between 2002 and 2014, Jacques Raynaud was a member of the Board of Directors of the ARC Foundation of which he was Chairman between 2005 and 2014.

Previously, Jacques Raynaud spent most of his career in the pharmaceutical industry. After four years of research on behalf of Nestlé (Switzerland) and Esso Research (USA), he joined Roussel Uclaf in 1969 to become a member of the Directorate of Hoechst Marion Roussel France in 1998. Following the merger with Aventis he was appointed to head the Romainville Research Centre and joined the International Committee in Research and Development of Aventis.

The ARC Foundation is the first 100% French foundation dedicated to cancer research.
In 2014, the ARC Foundation spent nearly 28 million euros for its social missions. Its resources come exclusively from the generosity of its donors and testators.

Jacques Raynaud is WIN’s Advisor to the Operational Team.


Why WIN